Technical Analysis for MEIP - MEI Pharma, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| See historical MEIP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 19 | NR7 | Range Contraction | 0.00% |
| Mar 19 | Inside Day | Range Contraction | 0.00% |
| Mar 18 | MACD Bearish Signal Line Cross | Bearish | 1.99% |
| Mar 18 | Shooting Star Candlestick | Bearish | 1.99% |
| Mar 18 | Down 3 Days in a Row | Weakness | 1.99% |
| Mar 15 | 20 DMA Support | Bullish | 0.66% |
| Mar 14 | Doji - Bearish? | Reversal | -0.32% |
| Mar 13 | MACD Bullish Signal Line Cross | Bullish | -0.65% |
| Mar 13 | Up 3 Days in a Row | Strength | -0.65% |
| Mar 12 | MACD Bearish Signal Line Cross | Bearish | 2.33% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-14
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Medicine Cancer Clinical Medicine Treatment Of Cancer Virotherapy Seattle Genetics Kite Pharma Hematologic Disorders Refractory Solid Tumors
Medicine Cancer Clinical Medicine Treatment Of Cancer Virotherapy Seattle Genetics Kite Pharma Hematologic Disorders Refractory Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MEIP news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 5.14 |
| 52 Week Low | 1.82 |
| Average Volume | 195,115 |
| 200-Day Moving Average | 3.463 |
| 50-Day Moving Average | 2.8516 |
| 20-Day Moving Average | 2.9675 |
| 10-Day Moving Average | 3.023 |
| Average True Range | 0.1719 |
| ADX | 20.98 |
| +DI | 20.2229 |
| -DI | 11.525 |
| Chandelier Exit (Long, 3 ATRs ) | 2.7584 |
| Chandelier Exit (Short, 3 ATRs ) | 3.2257 |
| Upper Bollinger Band | 3.2228 |
| Lower Bollinger Band | 2.7122 |
| Percent B (%b) | 0.7 |
| BandWidth | 17.206403 |
| MACD Line | 0.0678 |
| MACD Signal Line | 0.0706 |
| MACD Histogram | -0.0028 |
| Fundamentals | Value |
|---|---|
| Market Cap | 113.4 Million |
| Num Shares | 36.9 Million |
| EPS | 0.07 |
| Price-to-Earnings (P/E) Ratio | 43.86 |
| Price-to-Sales | 4.35 |
| Price-to-Book | 1.98 |
| PEG Ratio | 23.80 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.21 | ||||
| Resistance 3 (R3) | 3.21 | 3.15 | 3.19 | ||
| Resistance 2 (R2) | 3.15 | 3.11 | 3.15 | 3.18 | |
| Resistance 1 (R1) | 3.11 | 3.09 | 3.13 | 3.12 | 3.17 |
| Pivot Point | 3.06 | 3.06 | 3.07 | 3.06 | 3.06 |
| Support 1 (S1) | 3.02 | 3.02 | 3.04 | 3.02 | 2.97 |
| Support 2 (S2) | 2.96 | 3.00 | 2.96 | 2.96 | |
| Support 3 (S3) | 2.92 | 2.96 | 2.95 | ||
| Support 4 (S4) | 2.93 |
